XML 32 R22.htm IDEA: XBRL DOCUMENT
v3.22.2

Note 16 - License, Collaboration and Distribution Agreements | 6 Months Ended
--- | ---
Jun. 30, 2022
Notes to Financial Statements |
License, Collaboration, and Distribution Agreements [Text Block] | NOTE 16. LICENSE, COLLABORATION AND DISTRIBUTION AGREEMENTS Transactions under the Company’s major distribution agreements are recognized upon transfer of control of product sold to its major distribution partners at the amount of consideration that the Company expects to be entitled to. The Company records contract liabilities for the amounts that are estimated to be subject to significant reversal, including allowances for services, discounts, rebate programs, and product returns. The following table presents changes in the Company's contract assets and liabilities for the six months ended June 30, 2022 (in thousands):
|  | Balance at December 31, 2021 |  |  | Additions |  |  | Deductions |  |  | Balance at the end of the Period |
Contract liabilities: deferred revenue |  | $ | 2 |  |  | $ | 69 |  |  | $ | (2 | ) |  | $ | 69 |
Contract liabilities: accrued liabilities (includes contract assets) |  |  | 1,270 |  |  |  | 1,357 |  |  |  | (1,167 | ) |  |  | 1,460 |
Total |  | $ | 1,272 |  |  | $ | 1,426 |  |  | $ | (1,169 | ) |  | $ | 1,529 |
For the six months ended June 30, 2022 and 2021, the Company recognized the following revenue (in thousands):
|  | Six Months Ended June 30, |
|  | 2022 |  |  | 2021 |
Revenue recognized in the period from: |  |  |  |  |  |  |  |
Amounts included in contract liabilities at the beginning of the period: |  |  |  |  |  |  |  |
Performance obligations satisfied |  | $ | 1,270 |  |  | $ | 573 |
New activities in the period: |  |  |  |  |  |  |  |
Performance obligations satisfied |  |  | 4,404 |  |  |  | 3,367 |
|  | $ | 5,674 |  |  | $ | 3,940 |
Avenova Spray Pharmacy Distribution Agreements and Specialty Pharmacies Avenova Spray is made available in local pharmacies and major pharmacy retail chains under nationwide distribution agreements with McKesson Corporation, Cardinal Health and AmerisourceBergen. We have also entered into direct agreements with preferred pharmacy networks as part of our Partner Pharmacy Program. During the three months ended June 30, 2022 and 2021, the Company earned $0.1 million and $0.3 million, respectively, in sales revenue for its Avenova Spray product from these distribution and partner pharmacy agreements. The Company incurred net sales loss of $57 thousand during the six months ended June 30, 2022, and net sales revenue of $385 thousand during the six months ended June 30, 2021 for its Avenova Spray product from these distribution and partner pharmacy agreements. The net loss during the six months ended June 30, 2022, was the result of an increase in returns for expired product from a major pharmacy retail chain. Under the prescription Avenova Spray product distribution arrangements, the Company had a contract liability balance of $1.4 million and $0.9 million at June 30, 2022 and December 31, 2021, respectively. The contract liability is included in accrued liabilities in the condensed consolidated balance sheets. The Company also recorded a prepayment of $6 thousand and $19 thousand for rebates related to these distribution agreements as of June 30, 2022 and December 31, 2021, respectively, that is recorded in the prepaid expenses and other current assets in the condensed consolidated balance sheets. See Note 5, “Prepaid Expenses and Other Current Assets”. Over-the-Counter Sales of Avenova Spray Avenova Spray was launched online on June 1, 2019 direct to U.S. customers. Avenova Spray is offered primarily for sale on Amazon.com, the Company’s website (Avenova.com) and Walmart.com. Avenova Spray was launched at select CVS stores and online on CVS.com in February 2021. These channels provide the Company with more stable pricing and provide customers with easy access to our product. During the three and six months ended June 30, 2022, the revenue generated from over-the-counter Avenova Spray was $1.3 million and $2.7 million, respectively. During the three and six months ended June 30, 2021, the revenue generated from over-the-counter Avenova Spray was $1.3 million and $2.6 million, respectively. DERMAdoctor DERMAdoctor products are available through wholesale distribution relationships with third parties such as Costco, Amazon and others. The Company had a contract liability balance of $0.1 million and $0.4 million as of June 30, 2022, and December 31, 2021, respectively. The contract liability is included in accrued liabilities in the condensed consolidated balance sheets.

X
- Definition Tabular disclosure of license, collaboration, and distribution agreements. + References No definition available. + Details
Name: | nby_LicenseCollaborationAndDistributionAgreementsTextBlock
Namespace Prefix: | nby_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration